
Novartis narrowed its mid-term sales growth outlook to 5% annually through 2031 at its London investor day, as patent expirations weigh on the Swiss drugmaker.
“The current economic environment is forcing the industry to adapt and change for the better in order to survive. I believe this will result in survival of the fittest, and biotech will be a source of pride and innovation in the US for decades to come.”Listen to the Podcast for more coverage.






